一種血液救援系統使得外科醫生能夠在心血管手術術中與術后恢復患者的失血，從而將血液回輸給患者。該系統已經獲得了美國食品藥品管理局的許可。

該系統叫做CardioPAT，設計用于保證患者能夠輸到最安全的血液，也就是患者自己的血液。設備功能更加完善，使得系統十分適合在泵功能停止或者仍然跳動的心臟進行自身輸血。系統不僅能夠在手術室而且還能夠在重癥監護室搶救患者失血。CardioPAT是Haemonetics公司的產品，該公司開發了細胞拯救平臺并領導著外科血液救援市場。

Haemonetics估計每年大約有20％的冠狀動脈旁路手術使用泵功能停止技術。該公司已經在美國三家單位開始了消費者能夠接受的臨床試驗。公司指出：在前期歐洲的臨床試驗中，該系統表現良好。

英國James Cook大學醫院心胸外科臨床主任Andrew Owens主持了第一個臨床試驗，他評論說：“這是一項令人興奮的技術，將會為心臟病患者帶來巨大的利益。系統使得患者能夠回輸自己的血液，而且幫助血庫節約血液用于其它患者。”

Blood Salvage System for Bypass Surgery
 
A blood salvage system allows surgeons to recover blood lost by a patient during and after cardiovascular surgery and makes the blood available for transfusion back to the patient. The system has been cleared by the U.S. Food and Drug Administration (FDA).

Called CardioPAT, the system is designed to ensure that patients are transfused with the safest blood possible, which is their own. A device provides better functionality that makes the system ideally suited for providing autotransfusion during off-pump, or beating-heart, surgery. The system can salvage blood lost both in the operating room and during recovery in the intensive care unit. CardioPAT is the product of Haemonetics Corp. (Braintree, MA, USA), whose Cell Saver platform created and leads the surgical blood salvage market.

Haemonetics estimated that about 20% of annual coronary artery bypass graft surgeries use the off-pump surgical technique. The company is beginning customer-acceptance trials at three U.S. sites. In prior trials in Europe, the system performed very well, the company noted.

“This is a very exciting technique that will have compelling benefits for heart patients,” remarked Dr. Andrew Owens, clinical director of cardiothoracic surgery at the James Cook University Hospital (Middlesbrough, UK), who led the first trials. “The system gives patients the advantage of getting their own blood back, but also helps ensure that banked blood is available for other patients.”